Priority Review Is a Designation — the Voucher Is a Different Asset Entirely

FDA priority review and a priority review voucher share a name, a six-month clock, and almost nothing else. One is a designation FDA attaches to the application in front of it. The other is a transferable certificate a sponsor can redeem years later — on a completely different product — or sell to someone else's regulatory affairs team entirely. Conflating the two leads to filing strategies built on an asset that was never actually in play.

What priority review actually does

Priority review is FDA's commitment to act on a marketing application within six months of filing acceptance, rather than the ten-month standard review goal. The two-tier system traces to 1992, when FDA agreed to specific review-time goals under the Prescription Drug User Fee Act. FDA grants it to applications for drugs that would offer a meaningful improvement in the treatment, diagnosis, or prevention of a serious condition — a judgment made against the specific application, not the drug's therapeutic class or the sponsor's track record on other products. It does not lower the evidentiary bar: the same safety and effectiveness standard applies, on a faster clock.

What makes a voucher a different asset

A priority review voucher is not a byproduct of getting priority review — it is a separate award tied to a specific statutory program, independent of whether the approved product's own application received priority review at all. FDA currently runs two standing voucher programs:

• Rare pediatric disease (FD&C Act §529). Awarded when a sponsor wins approval of a qualifying drug or biologic for a rare pediatric disease. Rare pediatric disease designation itself is not required to receive the voucher.
• Tropical disease (FD&C Act §524). Awarded for an approved drug or biologic that prevents or treats a disease on FDA's tropical disease list, provided the application also otherwise qualifies for priority review and does not rely on an active ingredient already approved elsewhere.
• Medical countermeasure — expired. A third voucher program, for medical countermeasures against specified public health threats, sunset in October 2023 and no longer awards new vouchers. Treat any reference to it as historical.
• What transfers. The holder of a valid voucher — the original sponsor or a company that purchased it — can redeem it to apply the six-month clock to a different, later marketing application, paying the associated user fee at redemption.

A designation speeds review of the application it is granted for. A voucher is the thing you can put in a drawer and use — or sell — years later, on a product that has nothing to do with the one that earned it. The distinction that drives the deal, not just the designation

Why the rare pediatric disease voucher needs a status check

The tropical disease program is the only one of the three Congress created without a sunset provision; it remains in ongoing operation. The rare pediatric disease program has a different history: established in 2012 and reauthorized in 2016 and 2020, its authority to award new vouchers lapsed at the end of 2024. Congress revived it through the Consolidated Appropriations Act, 2026, enacted February 3, 2026, which extended FDA's authority to award rare pediatric disease vouchers through September 30, 2029. That is a real extension, not a permanent fix — the program's own legislative history is a record of lapse-and-reauthorize cycles, and FDA has separately proposed making it permanent. Treat the 2029 date as current, verify it on FDA's program page before relying on it, and do not assume the next reauthorization arrives on schedule.

None of this changes how FDA reviews the science. It changes what a sponsor can plan around, and what a corporate development team can safely put a number on. Programs built around rare disease development or pediatric indications are the ones most likely to have a real voucher question on the table, and the designation-versus-voucher distinction is the first thing to get right before that conversation goes further. For the mechanics of a related expedited designation, see how Fast Track designation does not buy rolling review either — a parallel case of a label getting conflated with a benefit it doesn't automatically carry.